Nosher Sadia, Fuad Sehrish, Mishra Nupur, Alrashid Zaid A, Rathod Bindu, Mohan Devyani, Basavanagowda Deepak M, Kaur Arveen, Heindl Stacey E
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2021 Feb 9;13(2):e13246. doi: 10.7759/cureus.13246.
This article will review current treatment options for multiple sclerosis (MS) while keeping our primary focus on alemtuzumab, as it is now approved in more than 65 countries. From a pathophysiological point of view, MS is a disabling disease impacting a patient's life both physically and mentally, leading to devastating social and economic impact. This review will elaborate on alemtuzumab's role in treating relapsing-remitting MS (RRMS) by comparing its efficacy, side effects, and monitoring with other disease-modifying therapies (DMTs) available in the market. It is a point of great concern not only for physicians but also for neurologists, nephrologists, endocrinologists, dermatologists, and oncologists when encountering long-term effects of alemtuzumab in the life of treated MS patients. We hope that our review will not only benefit treating faculties but also those who are suffering from this devastating disease.
本文将回顾目前针对多发性硬化症（MS）的治疗方案，同时我们将主要聚焦于阿仑单抗，因为它目前已在65多个国家获得批准。从病理生理学角度来看，MS是一种致残性疾病，会在身体和心理上影响患者的生活，导致巨大的社会和经济影响。本综述将通过比较阿仑单抗与市场上其他疾病修正疗法（DMTs）的疗效、副作用和监测情况，阐述其在治疗复发缓解型多发性硬化症（RRMS）中的作用。当遇到阿仑单抗对接受治疗的MS患者生活产生的长期影响时，这不仅是医生，也是神经科医生、肾科医生、内分泌科医生、皮肤科医生和肿瘤科医生极为关注的问题。我们希望我们的综述不仅能使治疗人员受益，也能使那些患有这种毁灭性疾病的人受益。
